Lamellar’s preclinical drug development program is investigating and optimising the properties of LAMELLASOME™ Nucleic Acid Transfer technology to develop nucleic acid-based therapeutics for diseases with significant unmet medical needs and accelerated clinical paths.

LAMELLASOME™ Nucleic Acid Transfer Technology

LAMELLASOME™ technology is a proprietary Nucleic Acid Transfer platform with the capability to deliver a spectrum of active agents from microRNAs to plasmids.

The potential of the LAMELLASOME™ Nucleic Acid Transfer platform to assist in the transfer of a broad range of genetic material is demonstrated by the two lead products. 

© Copyright 2019 Lamellar